Get the Stockscreener App
2.49
3.75%
0.09
Pre-market:
2.48
-0.01
-0.40%
Codexis Inc stock is traded at $2.49, with a volume of 488.10K.
It is up +3.75% in the last 24 hours and up +1.22% over the past month.
Codexis Inc is a biotechnology company engaged in providing enzyme-based technology solutions to improve pharmaceutical manufacturing processes. The company operates through two key business areas: the ECO Synthesis manufacturing platform and small molecule pharma biocatalysis. The ECO Synthesis platform focuses on developing enzymatic processes for the large-scale manufacture of RNA interference therapeutics, while the biocatalysis business utilizes engineered enzymes to enhance efficiency, yield, and sustainability in small molecule drug manufacturing. Geographically, it derives maximum revenue from the Americas.
See More
Previous Close:
$2.40
Open:
$2.48
24h Volume:
488.10K
Relative Volume:
0.26
Market Cap:
$226.33M
Revenue:
$70.39M
Net Income/Loss:
$-43.97M
P/E Ratio:
-4.806
EPS:
-0.5181
Net Cash Flow:
$-23.85M
1W Performance:
-4.41%
1M Performance:
+1.22%
6M Performance:
+52.76%
1Y Performance:
+11.66%
1-Day Range:
$2.45
$2.5499
1-Week Range:
$2.33
$2.69
52-Week Range:
$0.9583
$3.87
Codexis Inc Stock (CDXS) Company Profile
Name
Codexis Inc
Sector
Industry
Phone
650-421-8100
Address
200 PENOBSCOT DRIVE, REDWOOD CITY, CA
Compare CDXS vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CDXS
Codexis Inc
|
2.49 | 226.33M | 70.39M | -43.97M | -23.85M | -0.5181 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Codexis Inc Stock (CDXS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-19-24 | Downgrade | The Benchmark Company | Buy → Hold |
| Jun-03-24 | Resumed | Jefferies | Buy |
| May-30-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-29-24 | Upgrade | The Benchmark Company | Hold → Buy |
| Nov-07-23 | Downgrade | The Benchmark Company | Buy → Hold |
| Aug-07-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| May-09-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-31-22 | Resumed | Piper Sandler | Overweight |
| Mar-02-22 | Resumed | Cowen | Outperform |
| Apr-12-21 | Initiated | Piper Sandler | Overweight |
| Mar-01-21 | Initiated | Stifel | Buy |
| Feb-26-21 | Reiterated | H.C. Wainwright | Buy |
| Mar-10-20 | Initiated | The Benchmark Company | Buy |
| Jan-17-19 | Upgrade | First Analysis Sec | Neutral → Outperform |
| May-16-18 | Initiated | Stephens | Overweight |
| Oct-13-17 | Reiterated | H.C. Wainwright | Buy |
| May-31-17 | Initiated | Jefferies | Buy |
| Jan-26-17 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| Jan-04-17 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jan-06-16 | Initiated | H.C. Wainwright | Buy |
View All
Codexis Inc Stock (CDXS) Latest News
CDXS Q1 2026 Earnings: EPS Beats Estimates by 28.26% Despite Revenue UncertaintiesMargin Improvement Report - newsline.com
Codexis (CDXS) Hovers Near Support as Consolidation ContinuesExtension Target - newsline.com
CDXS Stock Price, Quote & Chart - ChartMill
Codexis director Raymond de Vre sells $6,173 in shares - Investing.com UK
Codexis director Raymond de Vre sells $6,173 in shares By Investing.com - Investing.com Nigeria
Codexis (CDXS) director De Vre sells 2,605 shares to cover RSU tax liability - Stock Titan
CDXS Q1 2026 Earnings: EPS Beat Despite Revenue Uncertainty, Shares SlipOperating Income Trends - newsline.com
Why Did CDXS Stock Jump 7% Today? - Stocktwits
CDXS Q1 2026 Earnings: EPS Surprise of 28% Fails to Offset Revenue UncertaintyEarnings Revision Downgrade - newsline.com
CDXS Q1 2026 Earnings: Narrower-Than-Expected Loss Signals ProgressProduct Revenue Analysis - newsline.com
Codexis highlights stereochemistry advances for scalable RNA manufacturing at TIDES USA - Caledonian Record
Codexis Inc. (CDXS) Posts Modest Gains, Hovers Between Key Support and Resistance LevelsSpring Pattern - newsline.com
Codexis Inc. (CDXS) Climbs 4.4% as Shares Approach Key ResistanceIron Condor Alert - The Legal Advocate
CDXS Q1 2026 Earnings: Surprise EPS Beat Despite Revenue UncertaintyEarnings Per Share - thelegaladvocate.com
CDXS Q1 2026 Earnings: Narrower-Than-Expected Loss Fails to Lift SharesLow Estimate Range - thelegaladvocate.com
Codexis (CDXS) Slides 1.58% as Biotech Stock Tests Key Support at $2.37Growth Factor - The Legal Advocate
Codexis (CDXS) Q1 2026 Earnings: Why the Beat MattersPositive Surprise Momentum - newsline.com
Q1 2026 Codexis Inc Earnings Call Transcript - GuruFocus
Q3 2025 Codexis Inc Earnings Call Transcript - GuruFocus
TradingKey - TradingKey
US$6.58: That's What Analysts Think Codexis, Inc. (NASDAQ:CDXS) Is Worth After Its Latest Results - simplywall.st
Number of shareholders of Codexis, Inc. – NASDAQ:CDXS - TradingView
Earnings Release: Here's Why Analysts Cut Their Codexis, Inc. (NASDAQ:CDXS) Price Target To US$6.58 - Yahoo Finance
MSN Money - MSN
Codexis, Inc. (NASDAQ:CDXS) Q1 2026 Earnings Call Transcript - Insider Monkey
Craig-Hallum Maintains Codexis(CDXS.US) With Buy Rating, Announces Target Price $9 - Moomoo
Codexis (NASDAQ:CDXS) Issues Quarterly Earnings Results - MarketBeat
Codexis (CDXS) Q1 2026 Earnings Transcript - AOL.com
Codexis (CDXS) Reports Q1 2026 Earnings and Highlights Growth Pr - GuruFocus
Codexis reiterates $72M-$76M 2026 revenue outlook while targeting 0.5 kilogram ECO Synthesis scale by year-end - MSN
Codexis (CDXS) Reports Strong Q1 Revenue and Upcoming Data Prese - GuruFocus
Codexis, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Codexis (CDXS) Confident in Financial Stability Through 2027 - GuruFocus
Codexis: Q1 Earnings Snapshot - theheraldreview.com
Earnings call transcript: Codexis beats Q1 2026 EPS forecast, stock rises - Investing.com
Earnings call transcript: Codexis beats Q1 2026 EPS forecast, stock rises By Investing.com - Investing.com South Africa
Codexis (NASDAQ:CDXS) Q1 Results Beat Estimates as Company Reaffirms Full-Year Guidance - ChartMill
Codexis (CDXS) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
CDXS: Strong Q1 growth and expanding ECO Synthesis platform position the company for robust 2026 performance - TradingView
CDXS: Q1 2026 revenue doubled and gross margin rose to 71%, with ECO Synthesis gaining industry traction - TradingView
Codexis Q1 Earnings Call Highlights - MarketBeat
Codexis says it has cash through 2027 as siRNA plans advance - Stock Titan
Codexis Reports First Quarter 2026 Financial Results - The Manila Times
Codexis, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Revenue surges as Codexis (CDXS) narrows quarterly loss and manages debt load - Stock Titan
Codexis (NASDAQ: CDXS) Q1 2026 revenue hits $15.2M as net loss shrinks - Stock Titan
Codexis, Inc. Reiterates Earnings Guidance for the Full Year 2026 - marketscreener.com
Opaleye (NASDAQ: CDXS) holds 7.47% of Codexis, 6.785M shares - Stock Titan
Codexis Inc Stock (CDXS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):